Erythrocyte associated amyloid-β as potential biomarker to diagnose dementia

Michele Lauriola, Giulia Paroni, Filomena Ciccone, Grazia D’Onofrio, Leandro Cascavilla, Francesco Paris, Carolina Gravina, Maria Urbano, Davide Seripa, Antonio Greco

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Although it is known that Alzheimer’s disease (AD) is associated with the progressive accumulation of amyloid β-peptide (Aβ) in the human brain, its pathogenic role has to be completely clarified. Aβ moves from the bloodbrain barrier to the plasma and an increased Aβ production in brain could be associated with higher Aβ concentrations in blood. A recent study has evaluated Aβ40 and Aβ42 levels in human red blood cells (RBCs) with evidence of agedependent higher Aβ concentration in RBCs. Objective: The aim of the study was to investigate if erythrocyte associated Aβ (iAβ) levels could be different in subjects affected by dementia in comparison with controls and according to the patient’s cognitive impairment or different dementia subtypes. Method: To answer these questions we assessed iAβ40 and iAβ42 levels in 116 patients: 32 healthy controls, 39 with diagnosis of vascular dementia (VaD), 14 mild cognitive impairment (MCI) and 31 AD. Results: In this population we found significant differences in iAβ42 between controls and cognitive impaired patients. Moreover, iAβ42 significantly differed between dementia vs MCI. AD also showed different iAβ42 levels as compared to VaD. Conversely, no differences were found for iAβ40. All the analyses were adjusted for potential confounders like age, gender and Hb concentration. A direct correlation between increasing iAβ42 concentration and the progression of the cognitive decline using the MMSE score as continuous variable was also found. Conclusion: Our findings support the evidence that iAβ42 could be an instrument to early recognize dementia and predict cognitive impairment.

Original languageEnglish
Pages (from-to)381-385
Number of pages5
JournalCurrent Alzheimer Research
Volume15
Issue number4
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Amyloid
Dementia
Erythrocytes
Biomarkers
Alzheimer Disease
Vascular Dementia
Brain
Cognitive Dysfunction
Population

Keywords

  • Alzheimer’s disease
  • Amyloid β peptide
  • Aβ40
  • Biomarker
  • Cognitive impairment
  • Erythrocyte associated Aβ42

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Erythrocyte associated amyloid-β as potential biomarker to diagnose dementia. / Lauriola, Michele; Paroni, Giulia; Ciccone, Filomena; D’Onofrio, Grazia; Cascavilla, Leandro; Paris, Francesco; Gravina, Carolina; Urbano, Maria; Seripa, Davide; Greco, Antonio.

In: Current Alzheimer Research, Vol. 15, No. 4, 01.01.2018, p. 381-385.

Research output: Contribution to journalArticle

Lauriola, Michele ; Paroni, Giulia ; Ciccone, Filomena ; D’Onofrio, Grazia ; Cascavilla, Leandro ; Paris, Francesco ; Gravina, Carolina ; Urbano, Maria ; Seripa, Davide ; Greco, Antonio. / Erythrocyte associated amyloid-β as potential biomarker to diagnose dementia. In: Current Alzheimer Research. 2018 ; Vol. 15, No. 4. pp. 381-385.
@article{6f4f7e16ccf84ea4bd0413ce1ba74a9e,
title = "Erythrocyte associated amyloid-β as potential biomarker to diagnose dementia",
abstract = "Background: Although it is known that Alzheimer’s disease (AD) is associated with the progressive accumulation of amyloid β-peptide (Aβ) in the human brain, its pathogenic role has to be completely clarified. Aβ moves from the bloodbrain barrier to the plasma and an increased Aβ production in brain could be associated with higher Aβ concentrations in blood. A recent study has evaluated Aβ40 and Aβ42 levels in human red blood cells (RBCs) with evidence of agedependent higher Aβ concentration in RBCs. Objective: The aim of the study was to investigate if erythrocyte associated Aβ (iAβ) levels could be different in subjects affected by dementia in comparison with controls and according to the patient’s cognitive impairment or different dementia subtypes. Method: To answer these questions we assessed iAβ40 and iAβ42 levels in 116 patients: 32 healthy controls, 39 with diagnosis of vascular dementia (VaD), 14 mild cognitive impairment (MCI) and 31 AD. Results: In this population we found significant differences in iAβ42 between controls and cognitive impaired patients. Moreover, iAβ42 significantly differed between dementia vs MCI. AD also showed different iAβ42 levels as compared to VaD. Conversely, no differences were found for iAβ40. All the analyses were adjusted for potential confounders like age, gender and Hb concentration. A direct correlation between increasing iAβ42 concentration and the progression of the cognitive decline using the MMSE score as continuous variable was also found. Conclusion: Our findings support the evidence that iAβ42 could be an instrument to early recognize dementia and predict cognitive impairment.",
keywords = "Alzheimer’s disease, Amyloid β peptide, Aβ40, Biomarker, Cognitive impairment, Erythrocyte associated Aβ42",
author = "Michele Lauriola and Giulia Paroni and Filomena Ciccone and Grazia D’Onofrio and Leandro Cascavilla and Francesco Paris and Carolina Gravina and Maria Urbano and Davide Seripa and Antonio Greco",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1567205014666171110160556",
language = "English",
volume = "15",
pages = "381--385",
journal = "Current Alzheimer Research",
issn = "1567-2050",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Erythrocyte associated amyloid-β as potential biomarker to diagnose dementia

AU - Lauriola, Michele

AU - Paroni, Giulia

AU - Ciccone, Filomena

AU - D’Onofrio, Grazia

AU - Cascavilla, Leandro

AU - Paris, Francesco

AU - Gravina, Carolina

AU - Urbano, Maria

AU - Seripa, Davide

AU - Greco, Antonio

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Although it is known that Alzheimer’s disease (AD) is associated with the progressive accumulation of amyloid β-peptide (Aβ) in the human brain, its pathogenic role has to be completely clarified. Aβ moves from the bloodbrain barrier to the plasma and an increased Aβ production in brain could be associated with higher Aβ concentrations in blood. A recent study has evaluated Aβ40 and Aβ42 levels in human red blood cells (RBCs) with evidence of agedependent higher Aβ concentration in RBCs. Objective: The aim of the study was to investigate if erythrocyte associated Aβ (iAβ) levels could be different in subjects affected by dementia in comparison with controls and according to the patient’s cognitive impairment or different dementia subtypes. Method: To answer these questions we assessed iAβ40 and iAβ42 levels in 116 patients: 32 healthy controls, 39 with diagnosis of vascular dementia (VaD), 14 mild cognitive impairment (MCI) and 31 AD. Results: In this population we found significant differences in iAβ42 between controls and cognitive impaired patients. Moreover, iAβ42 significantly differed between dementia vs MCI. AD also showed different iAβ42 levels as compared to VaD. Conversely, no differences were found for iAβ40. All the analyses were adjusted for potential confounders like age, gender and Hb concentration. A direct correlation between increasing iAβ42 concentration and the progression of the cognitive decline using the MMSE score as continuous variable was also found. Conclusion: Our findings support the evidence that iAβ42 could be an instrument to early recognize dementia and predict cognitive impairment.

AB - Background: Although it is known that Alzheimer’s disease (AD) is associated with the progressive accumulation of amyloid β-peptide (Aβ) in the human brain, its pathogenic role has to be completely clarified. Aβ moves from the bloodbrain barrier to the plasma and an increased Aβ production in brain could be associated with higher Aβ concentrations in blood. A recent study has evaluated Aβ40 and Aβ42 levels in human red blood cells (RBCs) with evidence of agedependent higher Aβ concentration in RBCs. Objective: The aim of the study was to investigate if erythrocyte associated Aβ (iAβ) levels could be different in subjects affected by dementia in comparison with controls and according to the patient’s cognitive impairment or different dementia subtypes. Method: To answer these questions we assessed iAβ40 and iAβ42 levels in 116 patients: 32 healthy controls, 39 with diagnosis of vascular dementia (VaD), 14 mild cognitive impairment (MCI) and 31 AD. Results: In this population we found significant differences in iAβ42 between controls and cognitive impaired patients. Moreover, iAβ42 significantly differed between dementia vs MCI. AD also showed different iAβ42 levels as compared to VaD. Conversely, no differences were found for iAβ40. All the analyses were adjusted for potential confounders like age, gender and Hb concentration. A direct correlation between increasing iAβ42 concentration and the progression of the cognitive decline using the MMSE score as continuous variable was also found. Conclusion: Our findings support the evidence that iAβ42 could be an instrument to early recognize dementia and predict cognitive impairment.

KW - Alzheimer’s disease

KW - Amyloid β peptide

KW - Aβ40

KW - Biomarker

KW - Cognitive impairment

KW - Erythrocyte associated Aβ42

UR - http://www.scopus.com/inward/record.url?scp=85052570492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052570492&partnerID=8YFLogxK

U2 - 10.2174/1567205014666171110160556

DO - 10.2174/1567205014666171110160556

M3 - Article

C2 - 29125073

AN - SCOPUS:85052570492

VL - 15

SP - 381

EP - 385

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1567-2050

IS - 4

ER -